STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Technology Artificial Intelligence
chemistry-2

Nektar Therapeutics Surges After Positive Eczema Drug Trial Results

byLuca Blaumann
June 24, 2025
in Artificial Intelligence, Large-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Shares double as midstage study shows promising efficacy and safety for autoimmune treatment

Nektar Therapeutics (NKTR) saw its shares double in early trading Tuesday after the biotech firm announced encouraging results from a midstage clinical trial of its experimental eczema treatment, rezpegaldesleukin.

The global Phase 2b REZOLVE-AD study evaluated 393 patients with moderate-to-severe atopic dermatitis, commonly known as eczema. According to the company, the drug met its efficacy targets after just three subcutaneous doses administered over a 16-week period.

“These data from REZOLVE-AD show a fast onset of both EASI response and itch relief within the first few doses,” said Dr. Jonathan Silverberg, professor of dermatology at the George Washington University School of Medicine and Health Sciences. He emphasized that the drug avoided certain side effects common with other treatments, such as conjunctivitis, oral herpes, or ulcers—potentially giving it a safety advantage in the crowded eczema treatment market.

The treatment works by targeting regulatory T cells, or Tregs, a type of immune cell that helps modulate inflammation and maintain immune balance. Nektar CEO Howard W. Robin highlighted the broader implications of the study: “The results show the promise of Tregs as an important potential therapeutic modality to treat inflammatory skin disorders and other autoimmune conditions.”

The news marks a major milestone for Nektar, which has faced a series of challenges in recent years. The positive data not only signal a possible breakthrough in eczema care but could also reinvigorate investor confidence in the company’s broader Treg-based pipeline.

With a strong safety profile and rapid symptom relief, rezpegaldesleukin could emerge as a viable competitor in the growing market for eczema and autoimmune therapies—positioning Nektar for a potential comeback.

You might like this article:Wall Street’s Top Research Upgrades: Lyft, EA, Exelixis, Broadcom, MakeMyTrip

Tags: AIGrowthMoversNektar TherapeuticsNewsNKTRStock Market
Previous Post

Wall Street’s Top Research Upgrades: Lyft, EA, Exelixis, Broadcom, MakeMyTrip

Next Post

Coinbase Surges as Analysts Call It the ‘Amazon of Crypto’

Related Posts

semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

byLuca Blaumann
November 12, 2026
0

Cristiano Amon highlights strong semiconductor demand, supply shortages, and Qualcomm’s growing AI infrastructure ambitions despite widespread technology stock volatility. Qualcomm...

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

byLuca Blaumann
November 11, 2026
0

AI cloud infrastructure provider beats Wall Street expectations, raises full-year revenue guidance, and reports a $132.5 billion backlog amid continued...

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

byLiliana Vida
November 10, 2026
0

CoreWeave stock has lost about 65% from its peak as AI infrastructure shares sell off and data center projects draw...

Next Post

Coinbase Surges as Analysts Call It the 'Amazon of Crypto'

Latest News

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

Based on Your Interest

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
investing
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026

Recommended

Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Artificial Intelligence

IonQ Revenue Surges 336% to Record $173.8 Million as Quantum Computing Demand Accelerates

November 6, 2026
Artificial Intelligence

AMD Revenue Surges 45% as AI Demand Drives Record Data Center Growth

November 3, 2026
Stoxpo

Follow us on social media:

Highlights

  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates
  • CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results
  • D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

November 11, 2026

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.